Clinical Trial Search

Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001

Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…

Primary: Percentage of Participants With Negative Ice Cube Provocation Test at Week 24 — 37.5; 40.5 percentage of participants — p=0.9492

Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Part A — 4; 0 Participants

Primary: Duration of Urticaria Until Remission Since Chronic Urticaria Was Diagnosed. — 18.5; 54; 67.7 percentage of participants

Primary: Safety and Tolerability — 3; 7 Participants with a TEAE

Primary: Time to 50% Decline in Clinical Symptoms Measured by the Urticaria Activity Score Seven Day(UAS7) — 23; 12 days

Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score

Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants

Primary: Change From Baseline in Post-provocation Urticaria Activity Score (UASprovo) — -1.1; -0.5 scores on a scale — p=0.277

Primary: The Change in Diary-based Clinical Symptoms as Measured by the Urticaria Activity Score 7 (UAS7) — 20.46; 24.59; 18.83; 18 UAS7 Scores

Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale

Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants

Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants

Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants

Primary: Mean Pruritus Severity Score Over the First Week of Treatment — 1.02; 1.18 Units on a scale — p=<0.001

Primary: Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Day 57 — -19.16; -24.05; -11.25; -15.69 Score on a Scale — p=0.0559

Primary: Wheal Measurement — 0; 7.91; 0.32 mm

Primary: Change in Urticaria Activity Score 7 (UAS7) From Baseline to Week 4 — -6.91; -9.79; -19.93; -14.56 scores on a scale — p=0.1601

Primary: Change of Patient Rated Pruritus Score — -1.61; -1.50 score on a scale

Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants

Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses

Primary: Vibration Detection Threshold (VDT) — 26.3; 19 (um/sec)

Primary: Change in the Basophil Proteome — 4; 0; 3 Participants

Primary: Number of Participants With Adverse Events — 3 participants

Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants

Primary: Percent of Participants With an Urticaria Control Test [UCT] Score of Greater Than or Equal to 12 — 75.0 percent of participants

Primary: Percentage of Participants With Adverse Events — 78.3; 83.7 Percentage of participants

Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale

Primary: Clinical Reaction — 0; 0; 12; 8 Participants